BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 3549705)

  • 21. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
    Dominguez RA; Goldstein BJ; Jacobson AF; Steinbook RM
    J Clin Psychiatry; 1985 Mar; 46(3):84-7. PubMed ID: 3918993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of symptoms of atypical depression for differential drug treatment outcome.
    McGrath PJ; Stewart JW; Harrison WM; Ocepek-Welikson K; Rabkin JG; Nunes EN; Wager SG; Tricamo E; Quitkin FM; Klein DF
    J Clin Psychopharmacol; 1992 Jun; 12(3):197-202. PubMed ID: 1629387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maprotiline versus imipramine and placebo in neurotic depression.
    van der Velde CD
    J Clin Psychiatry; 1981 Apr; 42(4):138-41. PubMed ID: 7009592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nomifensine vs. imipramine in depressed inpatients.
    Fann WE; Lyle FA; Higginbotham W
    J Clin Psychiatry; 1984 Apr; 45(4 Pt 2):60-2. PubMed ID: 6370978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenelzine v imipramine in atypical depression. A preliminary report.
    Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin J; Tricamo E; Markowitz JS; Klein DF
    Arch Gen Psychiatry; 1984 Jul; 41(7):669-77. PubMed ID: 6375621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implications of restrictive diagnosis for compliance to antidepressant drug therapy: alprazolam versus imipramine.
    Overall JE; Donachie ND; Faillace LA
    J Clin Psychiatry; 1987 Feb; 48(2):51-4. PubMed ID: 3542984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viloxazine HCl in the treatment of endogenous depression: a standard (imipramine) controlled clinical study.
    McEvoy JP; Libiger J; Wilson WH; Ban TA; Berney S; Guy W
    J Clin Psychiatry; 1982 Mar; 43(3):111-2. PubMed ID: 7037758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antidepressant specificity in atypical depression.
    Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison WM; Markowitz JS; Rabkin JG; Tricamo E; Goetz DM; Klein DF
    Arch Gen Psychiatry; 1988 Feb; 45(2):129-37. PubMed ID: 3276282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression.
    McGrath PJ; Stewart JW; Nunes EV; Ocepek-Welikson K; Rabkin JG; Quitkin FM; Klein DF
    Am J Psychiatry; 1993 Jan; 150(1):118-23. PubMed ID: 8417553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    Cohn CK; Robinson DS; Roberts DL; Schwiderski UE; O'Brien K; Ieni JR
    J Clin Psychiatry; 1996; 57 Suppl 2():15-8. PubMed ID: 8626358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo.
    Quitkin FM; Stewart JW; McGrath PJ; Tricamo E; Rabkin JG; Ocepek-Welikson K; Nunes E; Harrison W; Klein DF
    Br J Psychiatry Suppl; 1993 Sep; (21):30-4. PubMed ID: 8217065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenelzine treatment of melancholia.
    McGrath PJ; Stewart JW; Harrison W; Wager S; Quitkin FM
    J Clin Psychiatry; 1986 Aug; 47(8):420-2. PubMed ID: 3525522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders.
    Baca E; Garcia-Garcia M; Porras-Chavarino A
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):57-65. PubMed ID: 14687858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study.
    Robinson DS; Lerfald SC; Bennett B; Laux D; Devereaux E; Kayser A; Corcella J; Albright D
    Psychopharmacol Bull; 1991; 27(1):31-9. PubMed ID: 1862204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine.
    Kosten TR; Frank JB; Dan E; McDougle CJ; Giller EL
    J Nerv Ment Dis; 1991 Jun; 179(6):366-70. PubMed ID: 2051152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
    Feiger AD
    Psychopharmacol Bull; 1996; 32(4):659-65. PubMed ID: 8993088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.
    Stark P; Hardison CD
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):53-8. PubMed ID: 3882682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment dexamethasone suppression test as a predictor of response to phenelzine.
    Janicak PG; Pandey GN; Sharma R; Boshes R; Bresnahan D; Davis JM
    J Clin Psychiatry; 1987 Dec; 48(12):480-2. PubMed ID: 3693333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term therapy for depression with trazodone.
    Fabre LF; Feighner JP
    J Clin Psychiatry; 1983 Jan; 44(1):17-21. PubMed ID: 6337131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder.
    Cohn JB; Wilcox C
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):26-31. PubMed ID: 3882677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.